Stock MOB MOBERG PHARMA AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials Moberg Pharma AB

Equities

MOB

SE0020353928

Pharmaceuticals

Market Closed - Nasdaq Stockholm
Other stock markets
 11:29:42 2024-05-13 EDT 		5-day change 1st Jan Change
27.86 SEK -11.56% Intraday chart for Moberg Pharma AB -28.42% +83.29%
05-07 Moberg Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
05-06 Moberg Pharma AB Announces MOB-015 Receives National Approvals for All Countries Included in the Decentralized Procedure CI

Valuation

Fiscal Period: December 2019 2020 2022 2023 2024 2025 2026
Capitalization 1 337.9 143.1 228 425 779 - -
Enterprise Value (EV) 1 -557.6 112.7 228 425 779 779 779
P/E ratio 0.58 x 6.8 x -11 x -11.4 x -39.8 x -39.8 x -55.7 x
Yield - - - - - - -
Capitalization / Revenue 21.7 x 2.83 x 1,101 x - 130 x 18.5 x 7.87 x
EV / Revenue 21.7 x 2.83 x 1,101 x - 130 x 18.5 x 7.87 x
EV / EBITDA -113 x 4.94 x -12.9 x -16.8 x -21.6 x -37.1 x 26.9 x
EV / FCF - -3.03 x - -2.7 x -10.8 x -19.5 x 130 x
FCF Yield - -33.1% - -37% -9.24% -5.13% 0.77%
Price to Book - 0.41 x - - - - -
Nbr of stocks (in thousands) 1,867 1,986 9,827 27,961 27,961 - -
Reference price 2 181.0 72.05 23.20 15.20 27.86 27.86 27.86
Announcement Date 19-09-27 20-08-11 23-02-07 24-02-13 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2022 2023 2024 2025 2026
Net sales 1 15.55 50.5 0.207 - 6 42 99
EBITDA 1 -3 29 -17.64 -25.36 -36 -21 29
EBIT 1 -4.22 26.4 -20.23 -27.46 -37 -24 6
Operating Margin -27.13% 52.28% -9,771.01% - -616.67% -57.14% 6.06%
Earnings before Tax (EBT) 1 -5.065 25.43 - -25.42 -36 -24 7
Net income 1 558.8 20.02 -15.71 -21.09 -29 -22 5
Net margin 3,592.74% 39.65% -7,589.37% - -483.33% -52.38% 5.05%
EPS 2 313.5 10.60 -2.100 -1.330 -0.7000 -0.7000 -0.5000
Free Cash Flow 1 - -47.3 - -157.3 -72 -40 6
FCF margin - -93.67% - - -1,200% -95.24% 6.06%
FCF Conversion (EBITDA) - - - - - - 20.69%
FCF Conversion (Net income) - - - - - - 120%
Dividend per Share - - - - - - -
Announcement Date 19-09-27 20-08-11 23-02-07 24-02-13 - - -
1SEK in Million2SEK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2022 2023 2024 2025 2026
Net Debt - - - - - - -
Net Cash position 895 30.4 - - - - -
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow 1 - -47.3 - -157 -72 -40 6
ROE (net income / shareholders' equity) -1.1% 2.76% - -3% - - -
ROA (Net income/ Total Assets) - 2.54% - - - - -
Assets 1 - 787.1 - - - - -
Book Value Per Share - 176.0 - - - - -
Cash Flow per Share - - - - - - -
Capex 32.4 51.3 - - - - -
Capex / Sales 208.28% 101.5% - - - - -
Announcement Date 19-09-27 20-08-11 23-02-07 24-02-13 - - -
1SEK in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
MOBERG PHARMA AB Stock Moberg Pharma AB
+83.29% 81.28M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+29.98% 684B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+30.34% 568B
JOHNSON & JOHNSON Stock Johnson & Johnson
-3.52% 361B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.59% 329B
ABBVIE INC. Stock AbbVie Inc.
+4.07% 284B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.21% 240B
NOVARTIS AG Stock Novartis AG
+9.66% 208B
ROCHE HOLDING AG Stock Roche Holding AG
-6.83% 200B
AMGEN INC. Stock Amgen Inc.
+7.09% 166B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. MOB Stock
  4. Financials Moberg Pharma AB
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW